Bolton Diane L, Song Kaimei, Tomaras Georgia D, Rao Srinivas, Roederer Mario
ImmunoTechnology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, United States.
Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, United States.
Vaccine. 2017 Jan 23;35(4):639-646. doi: 10.1016/j.vaccine.2016.12.008. Epub 2016 Dec 29.
Respiratory mucosa immunization is capable of eliciting both local and distal mucosal immune responses; it is a potentially powerful yet largely unused modality for vaccination against respiratory diseases. Targeting the lower versus upper airways by aerosol delivery alters the immunogenicity profile of a vaccine, although the full extent of this impact is not well characterized. We set out to define the cellular and humoral response profiles elicited by immunization via intranasal, small aerosol droplets, and large aerosol droplets. We compared responses following adenovirus-vectored vaccination by these routes in macaques, either for the generation of primary immune responses or for the boosting of previously primed systemic responses. Aerosol delivery (4 or 10μm diameter droplets, addressing lower or upper airways, respectively) generated the highest magnitude lung CD4 and CD8 T-cell responses, reaching 10-30% vaccine-specific levels in bronchoalveolar lavage cells. In contrast, intranasal delivery was less immunogenic with >10-fold lower peak lung T-cell responses. Systemic (blood) T-cell responses were only observed following 4μm aerosol (and parenteral) immunization, while all delivery routes elicited similar humoral responses. These data demonstrate distinct immune response profiles with each respiratory tract vaccination modality and suggest that small droplet aerosol offers several immunological advantages over other respiratory routes.
呼吸道黏膜免疫能够引发局部和远端黏膜免疫反应;它是一种针对呼吸道疾病进行疫苗接种的潜在强大但在很大程度上未被利用的方式。通过气溶胶递送靶向较低或较高气道会改变疫苗的免疫原性特征,尽管这种影响的全部程度尚未得到充分表征。我们着手确定通过鼻内、小气溶胶滴和大气溶胶滴免疫引发的细胞和体液反应谱。我们比较了猕猴通过这些途径进行腺病毒载体疫苗接种后产生的原发性免疫反应或增强先前引发的全身反应的情况。气溶胶递送(分别针对较低或较高气道的直径为4或10μm的液滴)产生了最高强度的肺部CD4和CD8 T细胞反应,在支气管肺泡灌洗细胞中达到10%-30%的疫苗特异性水平。相比之下,鼻内递送的免疫原性较低,肺部T细胞反应峰值低10倍以上。全身性(血液)T细胞反应仅在4μm气溶胶(和肠胃外)免疫后观察到,而所有递送途径引发的体液反应相似。这些数据表明每种呼吸道疫苗接种方式都有独特的免疫反应谱,并表明小气溶胶滴相对于其他呼吸道途径具有若干免疫学优势。